The effectiveness of TKIs depends on the presence of EGFR mutations, and patients with NSCLC receiving TKIs therapy have a longer progression-free survival (PFS) than those receiving chemotherapy alone [4]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.